New Combination Therapy Enhances Survival Rates in Advanced Breast Cancer Patients

Just now October 1, 2026 1 min read 📰 Medical Xpress

📋 Key Takeaway

A new treatment regimen combining giredestrant has shown to significantly improve progression-free survival in patients with advanced breast cancer. This study, published in the New England Journal of Medicine, highlights advancements in cancer treatment that could benefit Iranian patients facing similar health challenges. The findings underscore the importance of access to innovative therapies in Iran's healthcare system.

Patients with estrogen receptor-positive (ER+), HER-2-negative advanced breast cancer experienced significantly improved progression-free survival (PFS) when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD), compared with a standard combination approach. These findings, from the phase 3 evERA Breast Cancer study, were published today in the New England Journal of Medicine. Initial results of the evERA study were presented at the 2025 Congress of the European Society of Medical Oncology.